Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
American Journal of Clinical Dermatology · 2024
DOI: 10.1007/s40257-024-00855-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Clinical Dermatology, 2024. Verfasst von Lawrence F Eichenfield und 12 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, CA, USA. leichenfield@gmail.com. Hauptthemen laut MEDLINE: Nitriles, Pyrazoles, Pyrimidines, Dermatitis, Atopic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Incyte.
Abstract (Originalsprache)
BACKGROUND: Atopic dermatitis (AD), a highly pruritic, inflammatory skin disease, affects approximately 7% of adolescents globally. A topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor, demonstrated safety and efficacy among adolescents/adults in two phase 3 studies (TRuE-AD1/TRuE-AD2). OBJECTIVE: To describe safety and efficacy of 1.5% ruxolitinib cream versus vehicle and long-term disease control of ruxolitinib cream among adolescents aged 12-17 years from pooled phase 3 study data. METHODS: Patients [≥ 12 years old with AD for ≥ 2 years, Investigator's Global Assessment score (IGA) 2/3, and 3-20% affected body surface area (BSA) at baseline] were randomized 2:2:1 to ruxolitinib cream (0.75%/1.5%) or vehicle for 8 weeks of continuous use followed by a long-term safety (LTS) period up to 52 weeks with as-needed use. Patients originally applying vehicle were rerandomized 1:1 to 0.75%/1.5% ruxolitinib cream. Efficacy measures at week 8 included IGA treatment success (IGA-TS; i.e., score of 0/1 with ≥ 2 grade improvement from baseline), ≥ 75% improvement in Eczema Area and Severity Index (EASI-75), and ≥ 4-point improvement in itch numerical rating scale (NRS4). Measures of disease control during the LTS period included IGA score of 0 (clear) or 1 (almost clear) and percentage affected BSA. Safety was assessed throughout the study. RESULTS: Of 1249 randomized patients, 245 (19.6%) were aged 12-17 years. Of these, 45 patients were randomized to vehicle and 92 patients to 1.5% ruxolitinib cream. A total of 104/137 (75.9%) patients continued on 1.5% ruxolitinib cream in the LTS period [82/92 (89.1%) continued on 1.5% ruxolitinib cream; 22/45 (48.9%) patients on vehicle were reassigned to 1.5% ruxolitinib cream], and 83/104 (79.8%) of these patients completed the LTS period. At week 8, substantially more patients who applied 1.5% ruxolitinib cream versus vehicle achieved IGA-TS (50.6% versus 14.0%), EASI-75 (60.9% versus 34.9%), and NRS4 (52.1% versus 17.4%; P = 0.009). The mean (SD) reduction in itch NRS scores was significantly greater in patients applying 1.5% ruxolitinib cream versus vehicle from day 2 [- 0.9 (1.9) versus -0.2 (1.4); P = 0.03]. During the LTS period, mean (SD) trough steady-state ruxolitinib plasma concentrations at weeks 12/52 were 27.2 (55.7)/15.5 (31.5) nM. The percentage of patients achieving IGA score of 0 or 1 was sustained or further increased with 1.5% ruxolitinib cream; mean affected BSA was generally low (< 3%; i.e., mild disease). Through 52 weeks, application site reactions occurred in 1.8% of adolescent patients applying 1.5% ruxolitinib cream at any time; no patients had serious adverse events. There were no serious infections, malignancies, major adverse cardiovascular events, or thromboembolic events. CONCLUSIONS: Meaningful anti-inflammatory and antipruritic effects were demonstrated with 1.5% ruxolitinib cream in the subset of adolescent patients with AD, comparable with those observed in the overall study population; long-term, as-needed use maintained disease control and was well tolerated. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifiers NCT03745638 (registered 19 November 2018) and NCT03745651 (registered 19 November 2018).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, CA, USA. leichenfield@gmail.com.
- Rady Children's Hospital, 3020 Children's Way, Mail Code 5092, San Diego, CA, 92123, USA. leichenfield@gmail.com.
- Oregon Health and Science University, Portland, OR, USA.
- Alliance Clinical Trials and Probity Medical Research, Waterloo, ON, Canada.
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
- Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
Förderung
- Incyte
Zitieren
APA
Eichenfield, L. F., Simpson, E. L., Papp, K., Szepietowski, J. C., Blauvelt, A., Kircik, L., Silverberg, J. I., Siegfried, E. C., Kuligowski, M. E., Venturanza, M. E., Kallender, H., Ren, H., & Paller, A. S. (2024). Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-024-00855-2
Vancouver
Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, et al. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. American Journal of Clinical Dermatology. 2024. doi:10.1007/s40257-024-00855-2
BibTeX
@article{Eichenfield2024,
author = {Eichenfield, Lawrence F and Simpson, Eric L and Papp, Kim and Szepietowski, Jacek C and Blauvelt, Andrew and Kircik, Leon and Silverberg, Jonathan I and Siegfried, Elaine C and Kuligowski, Michael E and Venturanza, May E and Kallender, Howard and Ren, Haobo and Paller, Amy S},
title = {Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies},
journal = {American Journal of Clinical Dermatology},
year = {2024},
doi = {10.1007/s40257-024-00855-2}
}
EUVIMED